Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mogroside V is a natural cucurbitane glycoside and triterpenoid isolated from the fruit of Siraitia grosvenorii (monk fruit). It is intensely sweet—about 250 times sweeter than sucrose—and is widely used as a low-calorie natural sweetener in foods and beverages[1][3][5]. Mogroside V exhibits antioxidant properties and has demonstrated anti-inflammatory, anti-diabetic, and anti-carcinogenic effects in preclinical studies[1][5][7]. In cancer models, it inhibits tumor growth by promoting apoptosis and cell cycle arrest in pancreatic cancer cells as well as inhibiting angiogenesis[1][5]. Recent research also suggests neuroprotective effects; mogroside V can mitigate neurotoxicity and dopaminergic neuron loss in Parkinson’s disease models by restoring metabolic balance in affected brain regions[2]. Its mechanisms include modulation of oxidative stress pathways (e.g. inhibition of COX-2 expression/ROS production) but do not involve direct action on classic drug targets. Mogroside V is primarily developed for use as a food additive or dietary supplement rather than as a pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mogroside v.